metformin has been researched along with Fetal Growth Retardation in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Fetal Growth Retardation: Failure of a FETUS to attain expected GROWTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 9.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| " We compared patients who received metformin throughout pregnancy to those with no metformin exposure." | 8.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 5.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| "Prepubertal intervention with metformin reduces central adiposity and improves insulin sensitivity in non-obese catch-up SGA children." | 5.20 | Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. ( Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A, 2015) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 5.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| " We compared patients who received metformin throughout pregnancy to those with no metformin exposure." | 4.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Recent evidence suggests that metformin may prevent pre-eclampsia by reverting the angiogenic imbalance in maternal sera." | 3.96 | Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies. ( Heinonen, T; Huttala, O; Laivuori, H; Tihtonen, K; Toimela, T; Uotila, J; Virtanen, A, 2020) |
| "To assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre-eclampsia undergoing expectant management." | 1.91 | Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia. ( Bergkvist, J; Bergman, L; Cluver, CA; Geerts, L; Hall, DR; Imberg, H; Mol, BW; Tong, S; Walker, SP, 2023) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 1.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| "Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy." | 1.62 | Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. ( Brownfoot, F; Cannon, P; Cruickshank, T; Garcha, D; Hannan, NJ; Hyett, J; Illanes, SE; Jellins, J; Kaitu'u-Lino, TJ; Kandel, M; Keenan, E; MacDonald, TM; Masci, J; Middleton, A; Murphy, C; Murray, E; Myers, J; Nguyen, TV; Nien, JK; Pell, G; Pritchard, N; Roddy Mitchell, A; Schepeler, M; Tong, S; Walker, SP; Whigham, CA; Wong, GP, 2021) |
| "Metformin is an anti-hyperglycemic drug widely used for the treatment of insulin resistance and glucose intolerance and is currently considered for preventing large-for-gestational-age (LGA) offspring in pregnant women affected by obesity or diabetes." | 1.51 | Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses. ( Astiz, S; Encinas, T; Garcia-Contreras, C; Gonzalez-Bulnes, A; Heras-Molina, A; Pesantez-Pacheco, JL; Torres-Rovira, L; Vazquez-Gomez, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hufnagel, A | 1 |
| Fernandez-Twinn, DS | 1 |
| Blackmore, HL | 1 |
| Ashmore, TJ | 1 |
| Heaton, RA | 1 |
| Jenkins, B | 1 |
| Koulman, A | 1 |
| Hargreaves, IP | 1 |
| Aiken, CE | 1 |
| Ozanne, SE | 1 |
| Huang, C | 1 |
| Wu, D | 1 |
| Zhang, K | 1 |
| Khan, FA | 1 |
| Pandupuspitasari, NS | 1 |
| Wang, Y | 1 |
| Huo, L | 1 |
| Sun, F | 1 |
| Cluver, CA | 1 |
| Bergman, L | 1 |
| Bergkvist, J | 1 |
| Imberg, H | 1 |
| Geerts, L | 1 |
| Hall, DR | 1 |
| Mol, BW | 1 |
| Tong, S | 2 |
| Walker, SP | 2 |
| Virtanen, A | 1 |
| Huttala, O | 1 |
| Tihtonen, K | 1 |
| Toimela, T | 1 |
| Heinonen, T | 1 |
| Laivuori, H | 1 |
| Uotila, J | 1 |
| Racine, JL | 1 |
| Adams, JH | 1 |
| Antony, KM | 1 |
| Hoppe, KK | 1 |
| Iruretagoyena, JI | 1 |
| Stewart, KS | 1 |
| Eddy, A | 1 |
| Rhoades, JS | 1 |
| Garcha, D | 1 |
| MacDonald, TM | 1 |
| Hyett, J | 1 |
| Jellins, J | 1 |
| Myers, J | 1 |
| Illanes, SE | 1 |
| Nien, JK | 1 |
| Schepeler, M | 1 |
| Keenan, E | 1 |
| Whigham, CA | 1 |
| Cannon, P | 1 |
| Murray, E | 1 |
| Nguyen, TV | 1 |
| Kandel, M | 1 |
| Masci, J | 1 |
| Murphy, C | 1 |
| Cruickshank, T | 1 |
| Pritchard, N | 1 |
| Hannan, NJ | 1 |
| Brownfoot, F | 1 |
| Roddy Mitchell, A | 1 |
| Middleton, A | 1 |
| Pell, G | 1 |
| Wong, GP | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Garcia-Contreras, C | 1 |
| Vazquez-Gomez, M | 1 |
| Pesantez-Pacheco, JL | 1 |
| Torres-Rovira, L | 1 |
| Heras-Molina, A | 1 |
| Encinas, T | 1 |
| Astiz, S | 1 |
| Gonzalez-Bulnes, A | 1 |
| Díaz, M | 1 |
| Bassols, J | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Nawaz, FH | 1 |
| Rizvi, J | 1 |
2 trials available for metformin and Fetal Growth Retardation
| Article | Year |
|---|---|
Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.
Topics: Abdominal Fat; Adiposity; Anti-Obesity Agents; Biomarkers; Body Mass Index; Child; Cohort Studies; D | 2015 |
Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome.
Topics: Abortion, Habitual; Adult; Body Mass Index; Case-Control Studies; Diabetes, Gestational; Female; Fet | 2010 |
7 other studies available for metformin and Fetal Growth Retardation
| Article | Year |
|---|---|
Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance.
Topics: Animals; Diet, High-Fat; Female; Fetal Growth Retardation; Glucose Intolerance; Humans; Infectious D | 2022 |
Perfluorooctanoic acid alters the developmental trajectory of female germ cells and embryos in rodents and its potential mechanism.
Topics: Animals; Caprylates; Female; Fetal Growth Retardation; Fluorocarbons; Germ Cells; Humans; Melatonin; | 2022 |
Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia.
Topics: Cesarean Section; Female; Fetal Growth Retardation; Humans; Infant; Infant, Newborn; Metformin; Pre- | 2023 |
Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies.
Topics: Adult; Angiogenesis Inhibitors; Case-Control Studies; Dose-Response Relationship, Drug; Female; Feta | 2020 |
Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.
Topics: Adult; Birth Weight; Diabetes Mellitus, Type 2; Female; Fetal Growth Retardation; Humans; Hypertensi | 2021 |
Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Topics: Adult; Area Under Curve; Birth Weight; Cell Hypoxia; Delivery, Obstetric; Diabetes, Gestational; Ele | 2021 |
Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses.
Topics: Animals; Body Size; Body Weight; Female; Fetal Growth Retardation; Fetus; Metformin; Organ Size; Pre | 2019 |